Henry Schein, Inc. $HSIC Shares Sold by Clarkston Capital Partners LLC

Clarkston Capital Partners LLC reduced its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 5.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,499,600 shares of the company’s stock after selling 88,220 shares during the period. Henry Schein makes up about 2.1% of Clarkston Capital Partners LLC’s holdings, making the stock its 14th largest position. Clarkston Capital Partners LLC owned about 1.27% of Henry Schein worth $99,528,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. CYBER HORNET ETFs LLC acquired a new stake in shares of Henry Schein in the second quarter valued at about $25,000. MUFG Securities EMEA plc acquired a new position in Henry Schein during the second quarter worth about $27,000. Sentry Investment Management LLC grew its position in Henry Schein by 132.1% during the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after buying an additional 515 shares during the period. Evelyn Partners Investment Management Services Ltd purchased a new position in Henry Schein in the second quarter valued at about $62,000. Finally, Mather Group LLC. purchased a new position in Henry Schein in the third quarter valued at about $71,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Henry Schein news, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the sale, the director directly owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stanley M. Bergman sold 43,812 shares of Henry Schein stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $81.31, for a total value of $3,562,353.72. Following the completion of the sale, the chief executive officer owned 383,803 shares of the company’s stock, valued at $31,207,021.93. This trade represents a 10.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 101,712 shares of company stock worth $8,251,789. 1.14% of the stock is owned by company insiders.

Henry Schein Trading Down 3.2%

Shares of HSIC opened at $77.60 on Monday. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $89.29. The company has a market capitalization of $8.90 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 2.30 and a beta of 0.87. The stock has a fifty day moving average of $78.20 and a two-hundred day moving average of $72.63. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Mizuho boosted their price target on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the company an “outperform” rating in a research note on Monday, February 23rd. Wells Fargo & Company lifted their price objective on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Leerink Partners boosted their target price on Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 24th. Finally, Morgan Stanley raised their price target on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and a consensus price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.